Amendment to Schedule 13D Filing for CASI Pharmaceuticals, Inc.

This filing is an amendment to a Schedule 13D, relating to the ordinary shares of CASI Pharmaceuticals, Inc. The amendment details a convertible promissory note purchase agreement dated December 11, 2025, where ETP Global III Fund L.P. purchased a convertible note with a principal amount of US$5 million on February 19, 2026. This represents the third tranche of a US$20 million convertible note financing. The note can be converted into ordinary shares at a conversion price determined by the volume-weighted average closing price of the shares, with a floor of $1.00 and a ceiling of $2.00 per share. The filing also discloses the beneficial ownership of securities by various reporting persons, with Wei-Wu He, Ph.D. holding the largest percentage (53.0%) after the purchase. The proceeds from the note are intended for clinical trials in China and general operations.